1
Chronic fatigue is a debilitating and devastating disorder with widespread consequences 23 for both the patient and the persons around them, but effective treatment strategies are 24 lacking. The identification of novel genetic mouse models of chronic fatigue may prove 25 invaluable for the study of its underlying physiological mechanisms and for the testing of 26 treatments and interventions. A novel mutation in Slc2a4 (GLUT4) was identified in a 27 forward mutagenesis screen because affected mice showed abnormal daily patterns 28 and levels of wheel running consistent with chronic fatigue. This new mouse model may 29
shed light on the pathophysiology of chronic fatigue. 30
INTRODUCTION 31
Fatigue is a debilitating symptom comorbid with many disorders and disease states, and 32 may also present without readily identifiable associated disorders, the latter referred to 33 as idiopathic fatigue (1). Fatigue persisting 6 months or more is considered chronic 34 fatigue and if additional criteria are met, a diagnosis of Chronic Fatigue Syndrome (CFS) 35
can be made (2) (3) (4) . The Centers for Disease Control and Prevention define chronic 36 fatigue syndrome as "a debilitating and complex disorder characterized by intense 37 fatigue that is not improved by bed rest and that may be worsened by physical activity or 38 mental exertion". Fatigue is associated with increased disability, impaired functioning 39 and increased mortality (5) (6) (7) . Its negative impact on activity and overall quality of life 40 further increases the need for adequate and effective treatment, although this has 41 remained elusive. 42
The development of appropriate animal models to study the underlying 43 mechanisms of fatigue is crucial, but is hampered by the lack of a widely accepted 44 operational definition of fatigue (8, 9) . Currently there are several different types of 45 mouse models, including those based on forced activity (e.g., treadmill or swimming), 46 neurodegenerative disorders (e.g., Parkinson's or Huntington's disease), cancer and its 47 treatments, or aging, but by far the most common types of models involve fatigue 48
following an immune challenge (e.g., those mimicking viral or parasitic infection) (10-49 16) . A commonality shared by all of these model systems is a resulting alteration of 50 behavioral output, such as voluntary wheel running (9) . 51
The mouse is an ideal model organism to investigate physiological and 52 neurological pathways involved in fatigue (9, 17) . Although the psychological and 53 emotional aspects of fatigue may be somewhat difficult to study in mice, the behavioral 54 components are more readily comparable. Models based on reduced or altered 55 voluntary wheel-running activity mimic the reduced voluntary physical activity exhibited 56 by humans with fatigue. Wheel running is a robust behavior in rodents, and is amenable 57 to quantitative analysis (17) (18) (19) . Some characteristics that may imply fatigue in mice 58 when tested on running wheels include reduced daily amount of activity, changes in 59 pattern or day-night distribution, a lack of consolidated running with an increase in the 60 number of distinct bouts, or a delayed onset or shortened duration of the daily active 61
phase. 62
There is some indication that there are genetic components related to the 63 development and manifestation of fatigue (20) (21) (22) (23) . Polymorphisms in several human 64 candidate genes (e.g., the adrenergic receptor a1 (ADRA1A), the serotonin transporter 65 (5-HTT or SLC6A4) or receptor (HTR2A), tyrosine hydroxylase (TH), corticosteroid-66 binding globulin (CBG), corticotropin releasing hormone receptor 1 (CRHR1), the 67 cytokine IL-1B, neuronal PAS domain protein 2 (NPAS2), the nuclear receptor subfamily 68
3; group C, member 1 glucocorticoid receptor (NR3C1), and the glutamate receptor -69 ionotropic kinase 2 (GRIK2)) have been linked to both the occurrence and severity of 70 fatigue symptomology (24) (25) (26) (27) (28) (29) (30) . A study comparing chronic fatigue syndrome patients to 71 healthy controls using a single nucleotide polymorphism (SNP) chip with over 900, 000 72 SNPs identified 442 candidates associated with chronic fatigue syndrome, and 73 highlighted two genes never before associated with fatigue (C-type lectin domain family 74 4, member M (CLEC4M) and coiled-coil domain containing 157 protein (CCDC157)) 75 (31) . In addition, mice with mutations in several genes have shown phenotypes 76 consistent with fatigue (e.g., corticosteroid-binding globulin (CBG), recombinase 77 activating gene 2 (RAG2), and interleukin-10 (IL-10)) (32) (33) (34) . 78 We know that random mutagenesis paired with forward genetic screening has 79 proven invaluable in establishing and expanding understanding of gene function (35-80 43) . In the field of circadian rhythms, forward genetics has been a powerful tool for 81
identifying both clock and clock-controlled genes (44) . We systematically screen 82 randomly mutagenized mice on running wheels in search of lines exhibiting alterations 83 in voluntary wheel-running activity. We believe that the identification of mouse lines that 84 harbor mutations resulting in altered behavioral patterns consistent with chronic fatigue, 85 and the subsequent identification of the responsible gene(s) or pathways, will contribute 86 significantly to our understanding of the pathophysiology of this debilitating disorder. 87
As part of a larger phenotype-driven ENU mouse mutagenesis project (45), we 88 screened mice for abnormalities in the expression of voluntary wheel-running activity, 89 with the hope of identifying genes involved in behavioral chronic fatigue. We describe 90 the identification of two independent lines of mice stemming from a single mutagenized 91
founder showing profound alterations in amount, pattern and distribution of daily wheel 92 running resulting from a single point mutation (twiggy; MGI:5805978) in Slc2a4 93 encoding the insulin-responsive glucose transporter, GLUT4. To our knowledge, this is 94 the first description of impaired functioning of this gene resulting in extensive behavioral 95 abnormalities. The finding that a mutation in this gene results in widespread behavioral 96 modifications and altered expression of daily activity patterns indicates that its role is 97 likely more diverse than has previously been appreciated. 98
99

RESULTS
100
Mice show abnormal, low amplitude voluntary wheel-running activity patterns. 101
In a voluntary wheel-running screen designed to isolate mice with heritable abnormal 102 patterns of behavior, we identified two lines of mice showing abnormal activity 103 consistent with chronic fatigue (Fig. 1 ). These two lines both stemmed from a single, 104 third generation (G3) founder female identified as having low body weight ( Fig. S1 A) , 105 which we named 'twiggy' and which was backcrossed to wildtype C57BL/6J to produce 106 N2 progeny ( Fig. S1 B) . Two additional G3 pedigrees stemming from the same 107 mutagenized founder (G0) male also contained affected G3 mice with low body weight 108 (2 out of 8 mice and 3 out of 26 mice, respectively) but none of these G3s produced 109 enough offspring for heritability testing. N2 progeny of the twiggy G3 founder female 110 showed body weights within the normal range, but an intercross of N2 mice produced a 111 subset (~5-8 out of 57) that showed the low body-weight phenotype (Fig. S1B) . A 112 subsequent backcross of affected N2F2 mice to wildtype C57BL/6J produced N3 113 progeny that were unaffected, indicating that this phenotype is expressed in a non-sex-114 linked, recessive heritance pattern. Despite the low body-weight phenotype and overall 115 smaller appearance, affected animals were completely healthy, and there was no 116 observed effect on reproductive fitness. 117
Mice were maintained in two distinct lines following initial heritability testing (Fig. 118 S1 C and D; Table S1 ). The first is a backcross/intercross (B/Int-x) line generated and 119 maintained by backcrossing affected (presumably homozygous) mice to C57BL/6J, and 120 then intercrossing the resulting offspring, producing alternating generations of obligate 121 heterozygous carrier "B/Int-x (N#)" mice, and "B/Int-x (N#F2)" mice of all 3 possible 122 genotypes (+/+, +/m, and m/m; ~25%, ~50% and ~25%, respectively; Fig. S1 C and D -123 left panels; Table S1 ; where N# denotes the number of backcross generations). The 124 second is an incross (I-x) line generated and maintained by crossing affected siblings 125 with each other over successive generations beginning with the first N2F2 progeny 126 shown in Fig. S1 B, to produce a homozygous line ( were significantly lower for both males and females of the I-x line than those of the B/Int-134
x line ( Fig. S1 E) , there was no significant difference between the two lines in fasting 135 blood glucose ( Fig. S1 F) . Values for all mice tested were within the normal blood 136 glucose range for C57BL/6J mice reported by Jackson Labs (Center for Genome 137 Dynamics; CGDpheno1 glucose (plasma GLU, 4h fast); phenome.jax.org). 138
When mice stemming from these lines were housed in cages with free access to 139 a running wheel, a number of mice in the B/Int-x (N6F2) line showed a hypoactive and 140 disrupted pattern of voluntary wheel-running activity ( Fig. 1 A and B ). Representative 141 activity plots (actograms) of two mice of the B/Int-x (N6F2) line are shown, with one 142 exhibiting normal levels and patterns of activity ( Fig. 1 A) and one showing the abnormal 143 phenotype (Fig. 1 B) . In contrast, all the mice in the I-x (N2F10) line showed this same 144 (N2F10) line were backcrossed to C57BL/6J mice in a test cross (T-x (N3); Table S1), 148 none of the progeny showed the phenotype, and circadian, or daily, wheel-running 149 behavior was indistinguishable from that of wildtype mice ( Fig. 1 E) . Average waveforms 150 of 10 days of recording under a light-dark (LD) cycle clearly show that overall wheel-151 running activity levels are significantly decreased in mice of the I-x (N2F10) line ( Fig. 1 152 F). The B/Int-x (N6F2) line included some mice that showed the phenotype and some 153 that didn't, whereas none of the T-x (N3) mice were affected, and these showed a 154 normal circadian pattern of activity with high levels of nocturnal wheel running. 155
Quantification of total activity ( Fig. 1 G) , light phase activity ( Fig. 1 H) , and 156 number of activity bouts per day ( Fig. 1 I) recorded during the LD cycle, showed 157 significant differences among progeny of the three types of crosses, with mice of the I-x 158 (N2F10) line showing low activity, with higher levels of activity during the rest phase and 159 higher numbers of distinct activity bouts. Differences in activity levels were maintained 160 when mice were recorded in constant darkness (DD; Fig. 1 J) , and the amplitude of the 161 wheel running rhythm in affected mice was significantly lower than in unaffected mice 162 ( Fig. 1 K) . The period of the free-running circadian rhythm recorded in DD was 163 significantly longer for mice of the I-x (N2F10) line ( Fig. 1 L) , although these values fall 164 within the normal range for wildtype C57BL/6J (18) . To map the mutation, we crossed affected mice from both the I-x and the B/Int-x lines to 202 C57BL/10J mice, and then intercrossed the resulting M-x (F1) progeny (n=92) to 203 produce M-x (F2) mice (Table S1 ). In total, 207 M-x (F2) mice from 9 independent 204 matings were produced and were tested on running wheels under LD and DD conditions 205
for the presence of the behavioral phenotype ( Fig. 4 ). All data were compared to F1 and 206 F2 mice generated from crosses of wildtype C57BL/6J and C57BL/10J mice 207 (designated as WTB6B10F1 (n=63) and WTB6B10F2 (n=112), respectively). 208
Representative actograms recorded from two M-x (F2) mice showing the low-amplitude, 209 low activity, highly disrupted behavioral wheel-running phenotype are shown in Fig. 4 B 210 and C, with an unaffected mouse shown in Fig. 4 A. No WTB6B10F1, WTB6B10F2 or 211 M-x (F1) mouse exhibited this constellation of behavioral phenotypes, although some 212 individuals did show some of its component characteristics (e.g., low activity but no 213 increased running in the light phase or no lack of consolidation of nocturnal activity). 214
Mice of the M-x (F2) generation showed decreased activity recorded under LD (Fig. 4D ) 215
and DD ( Fig. 4E ), increased amount of activity in the light phase ( Fig. S4 A) , and a 216 lower amplitude rhythm recorded in DD ( Fig. 4F ). There was no significant difference 217 found in number of activity bouts per day ( Fig. S4 B) , and the period of the free-running 218 rhythm was not altered for M-x (F2) mice, although interestingly, the WTB6B10F2 mice 219 did show a significantly shorter period ( Fig. S4 C) . 220
Using a genome-wide SNP panel of markers designed to differentiate C57BL/6J 221 from C57BL/10J (Table S2) In order to identify the gene responsible for the abnormal phenotypes described, we 236 performed whole-exome sequencing (WES) of pooled DNA collected from mice of the I-237
x (N2F20) generation, and those from a test cross stemming from affected B/Int-x 238 (N11F2) mice (T-x (N11F3); N=16 for each line). Representative activity records of mice 239 in the various generations used for this experiment are shown in Fig. S5 A-F. Body-240 weight data collected at 8 weeks of age for both male and female mice in the I-x 241 (N2F20) and T-x (N11F3) generations, as well as for those of the B/Int-x (N11) and 242 B/Int-x (N1F2) used to produce the T-x (N11F3) mice, reveal that mice of both lines 243 chosen for WES have significantly lower body weight ( Fig. S5 G) . In addition, mice of 244 both presumptive homozygous lines (I-x (N2F20) and T-x (N11F3)) showed significantly 245 lower levels of activity in LD compared to mice from the B/Int-x (F1) and B/Int-x (F2) 246 generations ( Fig. S5 H) . Importantly, activity levels and wheel running patterns did not 247 differ between these two presumptive homozygous lines, indicating that both were, in 248 fact, homozygous for the same genetic mutation. Genotyping for this SNP revealed that all mice in the 2 test cross lines were 258 homozygous for the mutant allele of this gene, whereas mice in the B/Int-x lines showed 259 the expected Mendelian ratio of genotypes at this mutant locus. Surprisingly, western 260 blot analysis showed that homozygous mice had higher levels of protein in the 261 gastrocnemius muscle than heterozygotes and wildtype littermates ( Fig. 5 C) , indicating 262
that the mutation appears to result in protein accumulation or increased expression. 263
Despite the higher levels of accumulated protein, mice homozygous for the 264 twiggy mutation show phenotypes similar to those shown by GLUT4 knockout mice (46- their treatments, but can also be manifest independent of other comorbid diagnoses or 289 etiologies (51) (52) (53) . For those persons suffering from this debilitating disorder, and their 290 loved ones, effective treatments would be most welcome, but in order for new 291 treatments to be identified and developed, informative animal models of chronic fatigue 292 are crucial. We carried out a forward genetic screen in order to identify mouse lines 293
showing behavioral characteristic of chronic fatigue. We describe the identification of a 294 novel mutation in the Slc2a4 gene encoding GLUT4 that results in a distinct daily 295 voluntary wheel-running pattern that is consistent with chronic fatigue. Affected mice 296 homozygous for the twiggy mutation of Slc2a4 show a behavioral pattern consisting of 297 low, non-consolidated and messy wheel-running activity, with increased short bursts of 298 activity interrupting the rest phase. These mice sleep during times of the day that normal 299 nocturnal wildtype mice would never sleep (i.e., during the first half of the active phase). 300
This pattern of behavior is consistent with increased fatigability, and suggests that 301 impaired functioning of the insulin-responsive glucose transporter (GLUT4), or other 302 impairments in glucose regulation and homeostasis may play a role in the underlying 303 pathophysiology of chronic fatigue. 304
Additional phenotypic characteristics observed in Slc2a4 twgy/twgy homozygous 305 mice are consistent with a non-functioning GLUT4 transporter (46) . These 306 characteristics include a low body weight, impaired glucose tolerance response with a 307 normal baseline fasting blood glucose level, increased heart mass consistent with 308 cardiac hypertrophy, decreased exercise tolerance, and increased fatiguing response 309
with abnormal blood glucose and lactate levels following exercise. Surprisingly, although 310 these phenotypic characteristics largely match those described for the GLUT4 null 311 mouse (46) (47) (48) (49) (54) (55) (56) , the protein levels in Slc2a4 twgy/twgy homozygous mice were found 312 to be elevated, suggestive of protein accumulation due to impairments in turnover or 313 degradation of the protein, or compensatory upregulation. It is possible that the mutation 314 results in a malformation of GLUT4 that interferes with its translocation or fusion to the 315 plasma membrane, or that it impairs its function as a glucose transporter. Either of these Slc2a4 +/twgy mice were indistinguishable from their wildtype littermates and/or wildtype 331 C57BL/6J controls. This is in sharp contrast to the GLUT4 knockout heterozygous 332 mouse that exhibits phenotypes consistent with diabetes (63) (64) (65) (66) . It has been suggested 333 that this diabetic phenotype, which is manifest in only a subpopulation of the 334 heterozygous knockouts and appears to vary with age, could be an artifact of genetic 335 background; however, this remains an open issue (64) . In addition, GLUT4 protein 336 levels are diminished in heterozygous GLUT4 knockout mice (63) (64) (65) (66) . In contrast, 337 protein levels of GLUT4 were unchanged in the muscle of Slc2a4 +/twgy mice. They were 338 not diminished as in the heterozygous knockout, absent as in the homozygous 339 knockout, nor elevated as in the Slc2a4 twgy/twgy mice. This finding reinforces the idea that 340 this mutation resulting in a premature stop in exon 10 of the gene does not simply knock 341 out GLUT4, and therefore it represents a novel model that can be used to further 342 characterize GLUT4 functioning. 343
The GLUT4 glucose transporter was historically considered a peripheral-acting 344 glucose channel, with expression thought to be limited to muscle, adipose tissues, and 345 heart (67, 68) . Recent studies have shown that it is, in fact, expressed more widely and 346 can also be found in distinct neuronal populations throughout the brain in mice (69) . 347
This more varied expression pattern and anatomical localization suggests that GLUT4 348 functions are more complex than simply a shunt for glucose in peripheral tissues. For 349 example, a very recent study shows that GLUT4 functions to maintain neuronal, and 350 specifically synaptic, energy requirements and is essential for maintaining extended 351 synaptic transmission (70) . The use of conditional genetic tools has also shed more light 352 on the diverse functions of GLUT4. Interfering with insulin signaling specifically in all 353 tissues expressing GLUT4 results in a diabetic phenotype that is due, at least in part, to 354 impaired insulin signaling in neuronal populations (71) . It is interesting to note that these 355 mice showed decreased body weight, but did not show any alterations in activity 356 amounts or patterns (71) . Mice with GLUT4 removed selectively from the brain show 357 that neuronal GLUT4 is critical for assessing and reacting to changes in blood glucose 358 levels (72); however, it is possible that some of these effects are non-specific Cre-driver 359 related since Nestin-Cre is expressed peripherally and mice carrying this transgene 360 have been shown to have metabolic phenotypes (73) . Work has been initiated to try to 361 identify the function of distinct subgroups of GLUT4 neurons using methods to isolate 362 and/or selectively ablate those expressing this gene (74, 75) . The removal of 363 hypothalamic neurons expressing GLUT4 resulted in metabolic changes that are 364 consistent with impaired energy utilization and homeostatic processes, but did not result 365 in locomotor deficits (75) . These mice ate less and lost weight, had altered oxygen 366 consumption and energy expenditure, and increased fasting blood glucose and aberrant 367 glucose tolerance responses, but the amount and daily pattern of activity remained 368 unchanged. These mice did, however, show a decreased activity response to an 369 overnight fast, and did not increase activity levels as much as unablated controls (75) . 370
Clearly, the use of these genetic tools to conditionally manipulate the expression of 371 GLUT4 in anatomically and temporally controlled ways will be critical in fully 372 characterizing the function of this glucose transporter. This should allow for the 373 determination of exactly how GLUT4 removal or altered function results in the seemingly 374 varied array of phenotypic outcomes described in the literature to date. 375
The identification of a novel mutation in the Slc2a4 gene resulting in a 376 constellation of abnormal behavioral characteristics consistent with chronic fatigue was 377 somewhat surprising, but not necessarily unexpected. It seems logical that impaired 378 glucose processing and homeostasis, with a concomitant altered tolerance of exercise, 379 would result in aberrant patterns of voluntary wheel-running activity as well. Voluntary 380 wheel running is increased in mice overexpressing GLUT4 in muscle (76) , but GLUT4 381 expression levels did not differ between active and inactive mouse strains (77) . It is 382 likely, however, that impaired glucose transport and cellular utilization would have some 383 effect on voluntary sustained activity. Switching from predominantly glucose to fatty acid 384 fuel utilization in muscle, either by transgenic or pharmacologic manipulation of the 385 peroxisome proliferator-activated receptor delta (PPARδ) pathway, increases exercise 386 endurance in mice (78) (79) (80) . Whether or not this increase in exercise capacity translates 387
into an increase in voluntary activity remains to be fully elucidated. For instance, mice 388 deficient in both cryptochrome 1 and 2 (Cry1/2 dKO) ran faster and for longer distances 389 than wildtype or single knockout controls on a treadmill task, presumably through de-390 repression of PPARδ activity; however, these mice showed decreased daily voluntary 391 wheel-running behavior (81) . It remains to be determined whether or not treatment of 392 Slc2a4 twgy/twgy mice with exercise mimetics would normalize some of the behavioral 393 abnormalities in wheel running that we observed (82) . This may prove informative to the 394 investigation of how these novel pharmacological treatments may apply to patients with 395 chronic fatigue, for whom voluntary exercise programs have been less than successful. 396
Fatigue, and alterations in the activity of daily living are well-described side 397 effects and symptoms of both type I and type II diabetes (83) (84) (85) . Like fatigue in other 398 patient populations, fatigue in diabetes is associated with physiological, psychological 399 and lifestyle variables, but may be exacerbated by fluctuations in blood glucose levels 400 and homeostasis. There is also some evidence suggestive of abnormal metabolic 401 responses in chronically fatigued patients, with abnormalities in energy and sugar 402 metabolism comprising one of the three main categories of pathways identified (86) . 403
The identification of abnormalities in metabolic pathways in chronic fatigue, both as 404 candidates for geared treatment options, and as potential biological markers that can be 405 used to differentially diagnose various subtypes of the disorder, have received an 406 increase in scientific focus recently (87, 88) . 407
Using an unbiased, forward genetic ENU mutagenesis screen for chronic fatigue, 408
we identified mice with a mutated form of the GLUT4 transporter; however, we are by no 409 means suggesting that mutations in GLUT4, or impaired glucose transport underlie all 410 manifestations of fatigue, although it may play a role in at least a subset of cases. 411
Rather, it is likely that chronic fatigue represents a persistent altered homeostatic state 412 in response to a variety of triggers and physiological adaptations (87) . It is hoped that 413 additional screening of mutagenized mouse lines for abnormalities in the expression of 414 voluntary wheel-running behavior will yield additional candidate genes and pathways 415 that are implemented in this complex disorder. In the mean time, studies to determine 416 the effectiveness of treatment strategies geared towards normalizing glucose 417 processing and transport in the Slc2a4 twiggy mice and other mouse models of chronic 418 fatigue may hold promise. In addition, assessing glucose tolerance in patients for whom 419 fatigue remains an unexplained symptom may be warranted. 420
421
MATERIALS AND METHODS 422
Animals and Housing 423
All mice were group housed in standard mouse cages under a 12:12 LD cycle (lights on 424 at 6:00 AM) with water and regular mouse chow (2018 Teklad Global 18% Protein 425 Rodent Diet, Envigo, Madison, WI, USA) available ad libitum, unless otherwise stated. 426
Mice were produced in our colony from strategic crosses, or were ordered from an in-427 house breeding core facility (Mouse Breeding Core, Wakeland lab, UT Southwestern 428
Medical Center, Dallas, TX, USA), which orders its breeding mice from Jackson Labs 429 (Bar Harbor, ME, USA). Some wildtype C57BL/6J mice were also ordered from Jackson The generation of N-Ethyl-N-nitrosourea (ENU; Sigma; catalog #N3385) mutagenized 441 mice and their progeny for initial high-throughput screening was described previously 442 (45) . Briefly, male C57BL/6J mice (~6 weeks of age) were injected with 250 mg/kg of 443 ENU. Following a recovery period of ~6 weeks, these mice were crossed with wildtype 444 C57BL/6J females to produce generation 1 (G1) males which were again crossed to 445 wildtype C57BL/6J females to produce G2 females. These G2 females were 446 backcrossed to their G1 fathers to produce G3 mice of both sexes used for phenotype 447
screening. 448
More advanced generations of mice, further removed from the original G0 449 founders, were used for the more in depth behavioral phenotypic screening. Progeny of 450 selected lines of mice that were at least 8 weeks old were individually housed in 451 standard polycarbonate mouse cages (Fischer Scientific; catalog # 01-288-1B and 01-452 288-21) containing a 4.75" diameter stainless steel running wheel placed inside isolation 453 cabinets containing 12 to 24 cages each, as described previously (19) . Temperature 454 and humidity were monitored throughout, and the mice were initially recorded under a 455 12:12 LD cycle (green LEDs, ~100 lux at the level of the cage floor). Following the initial 456 Cassettes (DVM60 ME LP:90) from 20:00 to 21:30 (i.e., 2h to 3.5h into the dark phase). 481
Wheel running was recorded throughout this period as described above. The resulting 482 video was scored for behavioral arrest indicative of sleep by two researchers blind to 483 mouse identity. Periods of immobility with lowered posture lasting longer than 40 484 consecutive seconds were scored as sleep (89) . All mice produced in our colony were weighed at specific ages through development. At 488 weaning, and at regular intervals thereafter, mice were visually inspected for general 489 health and wellness. For the determination of blood glucose levels, mice were fasted for 490 4h during the middle of the light phase (a time when mice do not normally eat). Body 491 weights were measured at the beginning and the end of the 4h fast, and blood glucose 492 was determined from a small droplet of blood taken from the tip of the tail, using the 493
Precision Xtra blood glucose meters and glucose test strips (Abbott Diabetes Care Inc., 494
Almeda, CA, USA). At the end of experiments and phenotypic characterization, mice 495 were euthanized with CO 2 followed by cervical dislocation. In some cases, tissues 496 (tailtips, spleens and hearts) were collected for weighing or DNA extraction followed by 497 genotyping. 498
499
Mapping 500
Affected mice from the I-x and B/Int-x lines were selected and crossed with wildtype 501 C57BL/10J mice (Stock Number 000665, Jackson Labs, Bar Harbor, ME, USA) to 502 produce mapping (M-x) F1 mice that were intercrossed to produce F2 progeny. 503
Additional crosses of wildtype C57BL/6J and C57BL/10J were also set up to produce 504 control (WTB6B10) F1 and F2 mice. All mice produced were individually housed in 505 running-wheel cages after 8 weeks of age and their behavior was recorded in LD (for 3 506 weeks) and DD (for 3 weeks) as described above. Following behavioral testing, mice 507
were euthanized and spleens were collected, frozen onto dry ice, and then stored at -508 80°C. Spleen DNA from 74 selected mice (half presumptive homozygous mutants and 509 half presumptive wildtypes or heterozygotes) was extracted using phenol chloroform 510 genomic DNA extraction method. The final DNA pellet was suspended in RNAse free 511 H2O. Concentrations were determined with a NanoDrop spectrophotometer, and DNA 512 was genotyped using Taqman probes on Fluidigm platform using the 96.96 chip 513 according to manufacturer instructions as described previously (90) . QTL linkage 514 analysis was performed using R/QTL as described previously (90, 91) . Genotyping 515 failed for one spleen sample, and these data were subsequently removed from further 516 analyses. After initial DNA quality assessment on a 1.8% agarose gel and concentration 535 quantification using a Qubit 3.0 Fluorometer (Invitrogen, Carlsbad, CA USA), fragment 536 libraries were prepared using SureSelectXT2 HSQ Reagent Kit (Agilent Technologies, 537
Inc., Santa Clara, CA, USA). Samples were sheared on the Covaris S-2 sonicator 538 (Covaris, Woburn, MA, USA) and end-repaired, after which the 3' ends were adenylated 539 and barcoded with pre-capture indexing adapters. Following amplification and 540 purification, the sizes of the fragment libraries were assessed on the Agilent 2100 541
BioAnalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA) and concentrations 542 were once again determined by Qubit fluorometric quantitation. Samples were pooled in 543 equimolar amounts and captured with the SureSelectXT2 Target Enrichment System for 544
Mouse (Agilent Technologies, Inc., Santa Clara, CA, USA), followed by a final Qubit 545 concentration quantification, and were run on the Illumina NextSeq 500 platform 546 (Illumina Inc., San Diego, CA, USA) using 150PE SBS v2 chemistry. Sequence reads 547 were mapped to the Genome Reference Consortium GRCm38 reference genomic 548 sequence for C57BL/6J using BWA (92) . Both samples resulted in mean coverage 549 greater than 120X. Variants were called using the Genome Analysis ToolKit (GATK) 550 Optical Reaction Plates (Applied Biosystems, Inc., Foster City, CA, USA) with the 564 following thermo-cycling conditions: 95°C for 3 min followed by 40 cycles of 95°C for 3 565 sec and 62°C for 20 sec. 566 567
Glucose Tolerance Test 568
Progeny of select crosses were fasted for 4h during the middle of the light phase (a time 569 when mice do not normally eat). Body weights were measured at the beginning and the 570 end of the 4h fast, and initial blood glucose was determined from a small droplet of 571 blood taken from the tip of the tail using the Precision Xtra blood glucose meters and 572 glucose test strips (Abbott Diabetes Care Inc., Almeda, CA, USA). Mice were then given 573 an I.P. injection of 10% sterile glucose solution (1 g/kg; Sigma-Aldrich, St. Louis, MO, 574 USA), and blood glucose values were measured again at 15, 30, 45, 60 and 120 min 575 post injection. 576 577
Endurance Treadmill Test 578
To test exercise endurance capacity, mice of both sexes from selected crosses were 579 run on a progressive treadmill running protocol. The mice were acclimatized to the 580 motorized treadmill (Animal Treadmill Exer-3/6, Columbus Instruments, Columbus, OH, 581 USA) for two days prior to the endurance test. Day 1 of acclimatization lasted 20 min 582 consisting of 5 min on the treadmill at rest (0 m/min), 5 min at 8 m/min, 5 min at 10 583 m/min, followed by 5 min of rest (0 m/min). Day 2 also lasted 20 min and consisted of 5 584 min on the treadmill at rest (0 m/min), 5 min at 10 m/min, 5 min at 12 m/min, followed by 585 5 min of rest (0 m/min). On day 3, mice performed the endurance test to exhaustion, 586 defined as when the mouse spent more than 5 sec on the shock grid (0.1 mA x163 V 587 and 1 Hz) without re-engaging with the treadmill, as described previously (95). The mice 588 ran at a speed of 10 m/min for the first 40 min, then the rate was increased at 1 m/min 589 every 10 min until the speed reached 13 m/min, at which point the speed was increased 590 at a rate of 1 m/min every 5 min until exhaustion. Mice were then removed from the 591 treadmill and blood glucose and lactate were immediately measured from tail blood 592 using hand-held analyzers for glucose (Bayer Contour Blood Glucose Meter, Ascensia 593 Diabetes Care US, Inc., Parsippany, NJ, USA) and lactate (Nova Biomedical Lactate 594 Plus Meter, Waltham, MA, USA). Mice were euthanized by decapitation, and muscles 595
were rapidly dissected and frozen on dry ice. All tissues were stored at -80°C until used. representative reads from each sample are shown at higher magnification at the bottom of the plot. A cartoon of the GLUT4 insulin-responsive glucose transporter with its 12 trans-membrane domains is shown in (B) with the A to T SNP location and resulting premature stop (Y440*) in exon 10 indicated with a red line. The mutation falls within the last extracellular loop and likely leads to a truncation of the cytoplasmic C-Terminus domain (indicated in grey). Protein abundance of GLUT4 in the gastrocnemius muscle of representative wildtype (+/+) and homozygous mutant (twgy/twgy) mice is shown in C with means ± SD and individual data points of +/+ or +/twgy (n=16) and twgy/twgy (n=14) plotted below. **** indicates significant difference between genotypes (p < 0.0001). See Fig. S5 for related data. Hours ± SD ** ** I-x (F20) 
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